Macrophage Pharma

What Macrophage Pharma does

Macrophage Therapeutics, Inc. (also referred to as Macrophage Pharma or "MT") is a privately held, clinical-stage biopharmaceutical company founded in 2014 and headquartered in Englewood Cliffs, New Jersey. The company is developing immuno-oncology and targeted anti-inflammatory therapeutics built on a proprietary CD206 receptor-based delivery platform that selectively binds to activated macrophages of the immune system. The platform exploits the fact that the CD206 receptor is uniquely expressed on activated (disease-causing) macrophages, and it reportedly achieves binding affinities 10,000x higher than current monoclonal antibodies. A pH-sensitive activation mechanism ensures the conjugated drug payload is released only after internalization into the target cell, modulating or destroying the macrophage depending on the payload class.

The company's pipeline comprises two product classes operating through the same targeting platform. The MT-2000 class is a targeted steroid intended to convert pro-inflammatory M1 macrophages into anti-inflammatory M2 macrophages, with the lead candidate MT-2002 being evaluated in animal models for indications including acute lung inflammation and non-alcoholic steatohepatitis (NASH). The MT-1000 class is a targeted apoptotic agent designed to deplete Tumor Associated Macrophages (TAMs), with the lead candidate MT-1002 being developed for use in combination with anti-cancer modalities including immunotherapies, chemotherapeutic agents, and radiation; preclinical data reportedly shows synergy with anti-HER2 monoclonal antibodies and favorable modulation of tumor immune infiltrates. The CD206 targeting mechanism has been clinically validated through an existing FDA/EMEA approved radiopharmaceutical, providing platform-level precedent.

The company is currently pre-commercial, with no marketed products and no disclosed pricing. Its stated go-to-market model is partnership-driven: management plans to license its TAM-depleting agents and partner with pharmaceutical companies developing complementary anti-cancer products for commercialization, rather than building an independent commercial infrastructure. Operating geographies are not disclosed beyond a single USA corporate entity (Macrophage Therapeutics, Inc.), and headcount is reported in the 1-10 employee range. Capital formation to date consists of a single disclosed financing round of approximately $10.95 million closed on January 9, 2017 (Series 2), led by Sixth Element Capital with participation from Aglaia BioMedical Ventures, M Ventures, and Novo Holdings.

Name

Macrophage Pharma

Legal name

Macrophage Therapeutics, Inc.

Website

https://macrophagetx.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Macrophage Therapeutics is a clinical-stage biopharmaceutical company developing CD206 receptor-targeted therapeutics, including MT-2000 class anti-inflammatory targeted steroids and MT-1000 class tumor-associated macrophage-depleting agents for immuno-oncology applications. It plans to commercialize through licensing and partnership with pharmaceutical companies developing complementary anti-cancer products.

Ownership category

akta.pro rank

Product category

Immuno-oncology and targeted anti-inflammatory therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Cytokines, Interferons & Immunomodulatory Proteins (HLAAAAAC)

Keywords

• Immuno-oncology therapeutics
• Targeted anti-inflammatory agents
• Macrophage-targeted drug delivery
• Tumor-associated macrophage depletion
• CD206 receptor platform

Headquarters

HQ city

Englewood Cliffs

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Core offering

Macrophage Therapeutics is developing novel immuno-oncology and targeted anti-inflammatory therapeutics based on its proprietary Activated Macrophage targeting platform. The company's CD206 receptor-based delivery system has binding affinities 10,000X higher than conventional antibodies and uses pH-sensitive drug activation to precisely target disease-causing pro-inflammatory M1 macrophages (MT-2000 class) and tumor-associated macrophages (MT-1000 class). Lead candidates include MT-2002 for inflammatory conditions and MT-1002 for oncology applications in combination with anti-cancer therapies.

Product overview

Macrophage Therapeutics is developing a portfolio of novel immuno-oncology and targeted anti-inflammatory therapeutics built on its proprietary Activated Macrophage targeting platform. The platform consists of two main product classes: the MT-2000 class (targeted steroids) for anti-inflammatory applications and the MT-1000 class (targeted apoptotic agents) for oncology. Specific products include MT-2002 for anti-inflammatory indications such as acute lung inflammation and non-alcoholic steatohepatitis, and MT-1002 for tumor-associated macrophage depletion in cancer therapy. The CD206 receptor-based delivery system enables receptor-mediated delivery with pH-sensitive drug activation, achieving 10,000X higher binding affinity than monoclonal antibodies.

Differentiator

Problem solved

Functional benefit

Products and services

• Activated Macrophage Targeting Platform Proprietary CD206 receptor-based delivery system that binds to the CD206 receptor only expressed on Activated Macrophages, internalizes a conjugated (inactivated) drug payload, and releases the active therapeutic via a pH drop inside the target cell to enable precise, selective therapeutic delivery.
• MT-2000 Class (Targeted Steroid) Proprietary targeted steroid product class designed to specifically modulate disease-causing pro-inflammatory M1 macrophages into anti-inflammatory M2 macrophages, eliminating the off-target toxicity associated with conventional steroid approaches.
• MT-1000 Class (Targeted Apoptotic Agent) Proprietary targeted apoptotic agent product class that targets and kills Tumor Associated Macrophages (TAMs) recruited by tumors to create a pro-tumor microenvironment, stimulating the body's endogenous immune system to attack the tumor.
• MT-2002 Specific anti-inflammatory candidate from the MT-2000 class that downregulates multiple pro-inflammatory cytokines and has demonstrated in vivo ability to reduce four pro-inflammatory markers in an acute lung inflammation model.
• MT-1002 Specific Tumor Associated Macrophage-depleting candidate from the MT-1000 class with preclinical combination data demonstrating improved efficacy with anti-HER2 mAbs, promotion of anti-cancer M1 macrophage infiltration, and remodeling of the immune microenvironment toward anti-tumor activity.

Quantifiable outcome

• 10,000X higher binding affinity compared to best monoclonal antibodies
• +6 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Innate Pharma: Clinical-stage immuno-oncology company developing antibody-based therapies that engage innate immune cells, including macrophages and NK cells, to treat cancer — directly comparable therapeutic modality and target cell biology.
• Surface Oncology: Immuno-oncology company focused on the tumor microenvironment and myeloid cell biology, including approaches to reprogram or deplete tumor-associated macrophages — highly comparable mechanistic thesis.
• Pionyr Immunotherapeutics: Developer of immuno-oncology antibodies targeting the tumor microenvironment, with programs designed to modulate myeloid cells including TAMs — comparable target cell and therapeutic class.
• Verseau Therapeutics: Cancer immunotherapy company developing antibodies that repolarize tumor-associated macrophages from pro-tumor M2 to anti-tumor M1 phenotypes — directly mirrors the M1/M2 modulation strategy of MT-2000 class.
• Pyxis Oncology: Clinical-stage oncology company building a pipeline of antibody-drug conjugates and immunotherapies that target tumor-microenvironment biology, including myeloid cell populations.

Emerging players

• Apexigen: Clinical-stage immuno-oncology company developing antibody therapeutics that target the tumor microenvironment, including myeloid and macrophage-related biology, with overlap in oncology indication strategy.
• Codiak BioSciences: Developer of engineered exosomes (engEx) designed to deliver therapeutic payloads to specific immune cells, including macrophages in the tumor microenvironment — comparable payload-delivery thesis to MT's CD206 backbone.
• Biotheus: China-based biotech developing antibody therapeutics for oncology and inflammation, with programs targeting immune cell biology including myeloid cells — relevant regional/emerging peer in macrophage-targeting therapeutics.

Broad incumbents

• Bristol-Myers Squibb: Large oncology incumbent with approved checkpoint inhibitors (Opdivo, Yervoy) and active myeloid-cell/macrophage research programs; sets the combination-therapy standard that MT-1000 would seek to enhance.
• Roche: Major oncology player with a deep checkpoint inhibitor portfolio (Tecentriq) and active research into tumor-microenvironment modulation, including macrophage biology; relevant as a potential combination partner and competitive benchmark.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Macrophage Pharma